{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:18:09Z","timestamp":1779333489149,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.02.074","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T04:42:29Z","timestamp":1616042549000},"page":"3445-3454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants"],"prefix":"10.1016","volume":"39","author":[{"given":"Md Ahsan","family":"Habib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-2259","authenticated-orcid":false,"given":"Roman","family":"Prymula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Carryn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ouzama","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Ravault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vytautas","family":"Usonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-0170","authenticated-orcid":false,"given":"Paul","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Povey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.074_b0005","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","article-title":"Varicella vaccination - the global experience","volume":"16","author":"Wutzler","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.074_b0010","unstructured":"European Centre for Disease Prevention and Control 2015. Varicella vaccination in the European Union. Available from https:\/\/www.ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/Varicella-Guidance-2015.pdf [last accessed March 25]."},{"key":"10.1016\/j.vaccine.2021.02.074_b0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.vaccine.2017.11.081","article-title":"One or two doses of live varicella virus-containing vaccines: efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life","volume":"36","author":"Henry","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.074_b0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.02.074_b0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1473-3099(18)30716-3","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial","volume":"19","author":"Povey","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.074_b0030","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(12)61461-5","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial","volume":"383","author":"Prymula","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.02.074_b0035","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.02.074_b0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12874-019-0687-y","article-title":"Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy","volume":"19","author":"Callegaro","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2021.02.074_b0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.02.074_b0050","series-title":"Correlates of vaccine-induced protection: methods and implications","author":"Nguipdop Djomo","year":"2013"},{"key":"10.1016\/j.vaccine.2021.02.074_b0055","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.074_b0060","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.074_b0065","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1002\/sim.1268","article-title":"Use of statistical models for evaluating antibody response as a correlate of protection against varicella","volume":"21","author":"Chan","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.02.074_b0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","article-title":"Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection","volume":"21","author":"Li","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.02.074_b0075","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1016\/j.vaccine.2020.03.009","article-title":"Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children","volume":"38","author":"Feyssaguet","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.074_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2288-13-29","article-title":"A threshold method for immunological correlates of protection","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2021.02.074_b0085","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/sim.2282","article-title":"A model for immunological correlates of protection","volume":"25","author":"Dunning","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.02.074_b0090","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1016\/j.vaccine.2019.07.049","article-title":"Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: a 10-year follow-up","volume":"37","author":"Carryn","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.074_b0095","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.074_b0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.074_b0105","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.02.074_b0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12874-015-0096-9","article-title":"Some extensions in continuous models for immunological correlates of protection","volume":"15","author":"Dunning","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2021.02.074_b0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006454-199201000-00006","article-title":"Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response","volume":"11","author":"White","year":"1992","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.02.074_b0120","first-page":"95","article-title":"Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies","volume":"41","author":"Freer","year":"2018","journal-title":"New Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.02.074_b0125","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0163-4453(17)30188-3","article-title":"Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?","volume":"74","author":"Gershon","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2021.02.074_b0130","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/infdis\/jiy403","article-title":"Immunobiology of varicella-zoster virus infection","volume":"218","author":"Laing","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.074_b0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1089\/vim.2017.0136","article-title":"Varicella virus vaccination in the United States","volume":"31","author":"Shaw","year":"2018","journal-title":"Viral Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:58:32Z","timestamp":1759402712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":27,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21002656"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.074","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}